Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT‐CN study

May 29, 2025Obesity (Silver Spring, Md.)

Tirzepatide's links to heart and metabolism benefits in Chinese adults: subgroup analysis of the SURMOUNT-CN study

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

At week 52, 37 participants achieved a normal BMI after treatment with tirzepatide.

Participants who lost a greater percentage of weight at 12 and 24 weeks showed significantly greater improvements in cardiometabolic markers.
Tirzepatide led to significant reductions in body weight, BMI, and waist circumference compared to placebo (p < 0.05).
The prevalence of metabolic syndrome decreased from 21.6% at baseline to 0% by week 52 among participants.
Improvements in cardiometabolic risk factors were particularly noted in Chinese adults who achieved a normal BMI.

AI simplified

OBJECTIVE: The objective of this study was to evaluate the association of tirzepatide with body weight, cardiometabolic markers, and metabolic syndrome in Chinese participants achieving normal body mass index (BMI) values by week 52 across baseline BMI subgroups.

METHODS: This post hoc analysis of SURMOUNT-CN assessed the association of tirzepatide with cardiometabolic risk factors in Chinese participants, categorized by Chinese-specific anthropometric cutoffs for BMI and waist circumference. The association of early weight loss (greater or less than median at 12 and 24 weeks) with cardiometabolic markers and metabolic syndrome was evaluated.

RESULTS: In this post hoc analysis (N = 177; tirzepatide 10 mg, n = 62; tirzepatide 15 mg, n = 57; placebo, n = 58), participants with greater weight reduction (greater than or equal to the median percentage loss at 12 and 24 weeks) showed significantly greater improvements in cardiometabolic markers. Tirzepatide also significantly reduced body weight, BMI, and waist circumference compared with placebo (p < 0.05). At week 52, 37 participants achieved a normal BMI (18.5-24 kg/m, Chinese criteria), and metabolic syndrome dropped from 21.6% at baseline to 0%. 2

CONCLUSIONS: Early weight loss with tirzepatide was associated with significant improvements in cardiometabolic risk factors, particularly in Chinese adults achieving a normal BMI by week 52, suggesting that early response may be associated with enhanced long-term metabolic health outcomes.

Full Text

Full text is available at the source.

View full text ↗

Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT‐CN study

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief